ALERT:

Prostate Cancer Clinical Trial 20203240

[LCID Study Number: 20203240]

Phase 3 Study of Early Intervention After RADICAl ProstaTEctomy w Androgen Deprivation Therapy w or w/o Darolutamide vs Placebo in Men at Risk of Prostate Cancer by Genomic Stratification (ERADICATE)

The purpose of this study is to compare the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer.

Disease/Condition: Prostate Cancer

Department: Hematology and Oncology

Location(s): Addison Gilbert Hospital; Beverly Hospital; Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody; Winchester Hospital

Primary Contact Email: [email protected]

Primary Contact Phone: 781-756-5095

Protocol #: 20203240
Principal Investigator(s): Brendan J. Connell
Study Coordinator(s): Carol Bovest
Trial Phase: Sponsor Initiated Study Phase 3